Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 36

1.

The ongoing saga of the mechanism(s) of MHC class I-restricted cross-presentation.

Grotzke JE, Sengupta D, Lu Q, Cresswell P.

Curr Opin Immunol. 2017 Jun;46:89-96. doi: 10.1016/j.coi.2017.03.015. Epub 2017 May 18. Review.

PMID:
28528219
2.

The role of cDC1s in vivo: CD8 T cell priming through cross-presentation.

Theisen D, Murphy K.

F1000Res. 2017 Feb 1;6:98. doi: 10.12688/f1000research.9997.1. eCollection 2017. Review.

3.

The Biology and Underlying Mechanisms of Cross-Presentation of Exogenous Antigens on MHC-I Molecules.

Cruz FM, Colbert JD, Merino E, Kriegsman BA, Rock KL.

Annu Rev Immunol. 2017 Apr 26;35:149-176. doi: 10.1146/annurev-immunol-041015-055254. Epub 2017 Jan 11. Review.

PMID:
28125356
4.

Increased translocation of antigens to endosomes and TLR4 mediated endosomal recruitment of TAP contribute to nicotine augmented cross-presentation.

Wang YY, Hu ChF, Li J, You X, Gao FG.

Oncotarget. 2016 Jun 21;7(25):38451-38466. doi: 10.18632/oncotarget.9498.

5.

The Combined Deficiency of Immunoproteasome Subunits Affects Both the Magnitude and Quality of Pathogen- and Genetic Vaccination-Induced CD8+ T Cell Responses to the Human Protozoan Parasite Trypanosoma cruzi.

Ersching J, Vasconcelos JR, Ferreira CP, Caetano BC, Machado AV, Bruna-Romero O, Baron MA, Ferreira LR, Cunha-Neto E, Rock KL, Gazzinelli RT, Rodrigues MM.

PLoS Pathog. 2016 Apr 29;12(4):e1005593. doi: 10.1371/journal.ppat.1005593. eCollection 2016 Apr.

6.

HIV Protease Inhibitor-Induced Cathepsin Modulation Alters Antigen Processing and Cross-Presentation.

Kourjian G, Rucevic M, Berberich MJ, Dinter J, Wambua D, Boucau J, Le Gall S.

J Immunol. 2016 May 1;196(9):3595-607. doi: 10.4049/jimmunol.1600055. Epub 2016 Mar 23.

7.

Prediction of T Cell Epitopes from Leishmania major Potentially Excreted/Secreted Proteins Inducing Granzyme B Production.

Naouar I, Boussoffara T, Chenik M, Gritli S, Ben Ahmed M, Belhadj Hmida N, Bahi-Jaber N, Bardi R, Gorgi Y, Ben Salah A, Louzir H.

PLoS One. 2016 Jan 15;11(1):e0147076. doi: 10.1371/journal.pone.0147076. eCollection 2016.

8.

CD8+ T cells in cutaneous leishmaniasis: the good, the bad, and the ugly.

Novais FO, Scott P.

Semin Immunopathol. 2015 May;37(3):251-9. doi: 10.1007/s00281-015-0475-7. Epub 2015 Mar 24. Review.

9.

Batf3-dependent CD103+ dendritic cells are major producers of IL-12 that drive local Th1 immunity against Leishmania major infection in mice.

Martínez-López M, Iborra S, Conde-Garrosa R, Sancho D.

Eur J Immunol. 2015 Jan;45(1):119-29. doi: 10.1002/eji.201444651. Epub 2014 Nov 28.

10.

The subcellular location of ovalbumin in Plasmodium berghei blood stages influences the magnitude of T-cell responses.

Lin JW, Shaw TN, Annoura T, Fougère A, Bouchier P, Chevalley-Maurel S, Kroeze H, Franke-Fayard B, Janse CJ, Couper KN, Khan SM.

Infect Immun. 2014 Nov;82(11):4654-65. doi: 10.1128/IAI.01940-14. Epub 2014 Aug 25.

11.

Experimental Validation of Multi-Epitope Peptides Including Promising MHC Class I- and II-Restricted Epitopes of Four Known Leishmania infantum Proteins.

Agallou M, Athanasiou E, Koutsoni O, Dotsika E, Karagouni E.

Front Immunol. 2014 Jun 10;5:268. doi: 10.3389/fimmu.2014.00268. eCollection 2014.

12.

Leishmania spp. Proteome Data Sets: A Comprehensive Resource for Vaccine Development to Target Visceral Leishmaniasis.

Aebischer T.

Front Immunol. 2014 Jun 10;5:260. doi: 10.3389/fimmu.2014.00260. eCollection 2014. Review.

13.

A role for NADPH oxidase in antigen presentation.

Gardiner GJ, Deffit SN, McLetchie S, Pérez L, Walline CC, Blum JS.

Front Immunol. 2013 Sep 23;4:295. doi: 10.3389/fimmu.2013.00295. Review.

14.

Use and abuse of dendritic cells by Toxoplasma gondii.

Sanecka A, Frickel EM.

Virulence. 2012 Nov 15;3(7):678-89. doi: 10.4161/viru.22833. Epub 2012 Nov 15. Review.

15.

CD8(+) T cells in leishmania infections: friends or foes?

Stäger S, Rafati S.

Front Immunol. 2012 Jan 24;3:5. doi: 10.3389/fimmu.2012.00005. eCollection 2012.

16.

Cross-presentation: how to get there - or how to get the ER.

Kreer C, Rauen J, Zehner M, Burgdorf S.

Front Immunol. 2012 Jan 3;2:87. doi: 10.3389/fimmu.2011.00087. eCollection 2011.

17.

Induction of protective CD4+ T cell-mediated immunity by a Leishmania peptide delivered in recombinant influenza viruses.

Kedzierska K, Curtis JM, Valkenburg SA, Hatton LA, Kiu H, Doherty PC, Kedzierski L.

PLoS One. 2012;7(3):e33161. doi: 10.1371/journal.pone.0033161. Epub 2012 Mar 21.

18.

Protein disulfide isomerase and host-pathogen interaction.

Stolf BS, Smyrnias I, Lopes LR, Vendramin A, Goto H, Laurindo FR, Shah AM, Santos CX.

ScientificWorldJournal. 2011;11:1749-61. doi: 10.1100/2011/289182. Epub 2011 Oct 18. Review.

19.

Tumor-derived autophagosome vaccine: mechanism of cross-presentation and therapeutic efficacy.

Li Y, Wang LX, Pang P, Cui Z, Aung S, Haley D, Fox BA, Urba WJ, Hu HM.

Clin Cancer Res. 2011 Nov 15;17(22):7047-57. doi: 10.1158/1078-0432.CCR-11-0951. Epub 2011 Nov 8.

20.

In silico analysis of six known Leishmania major antigens and in vitro evaluation of specific epitopes eliciting HLA-A2 restricted CD8 T cell response.

Seyed N, Zahedifard F, Safaiyan S, Gholami E, Doustdari F, Azadmanesh K, Mirzaei M, Saeedi Eslami N, Khadem Sadegh A, Eslami Far A, Sharifi I, Rafati S.

PLoS Negl Trop Dis. 2011 Sep;5(9):e1295. doi: 10.1371/journal.pntd.0001295. Epub 2011 Sep 6.

Supplemental Content

Support Center